# Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Krishnansu S. Tewari,Michael W. Sill,Richard T. Penson,Helen Huang,Lois M. Ramondetta,Lisa M. Landrum,Ana Oaknin,Thomas Reid,Mario M. Leitão,Helen E. Michael,Philip J. DiSaia,Larry J. Copeland,William T. Creasman,Frederick B. Stehman,Mark F. Brady,Robert A. Burger,J.T. Thigpen,Michael J. Birrer,Steven Waggoner,David H. Moore,Katherine Y. Look,Wui-Jin Koh,Bradley J. Monk |
| Citations | 686 |
| DOI | 10.1016/s0140-6736(17)31607-0 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://escholarship.org/uc/item/2rq1s1px |
| OpenAlex ID | https://openalex.org/W2742133220 |
| PMID | 28756902 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Robert A. Burger](https://scholariq.org/researchers/robert-a-burger/)
- [Bradley J. Monk](https://scholariq.org/researchers/bradley-j-monk/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Paper topics

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [14-3-3 protein interactions](https://scholariq.org/topics/14-3-3-protein-interactions/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.